Urology Times reached out to three urologists (selected randomly) and asked them each the following question: What advances in urology do you hope to see in 2020?
“It’s actually an exciting time for patients who have metastatic urothelial cancers and prostate cancers or advanced prostate cancers because there are a lot more products on the way, like the newer hormone agents for prostate cancer and the new immunologic agents like PARP inhibitors for different types of cancers. Those are all really interesting developments. I’d like to see more results in that sense. I think we will have more coming along there, and it will be good to see.
I think it will definitely help patients who have these diseases to have their lives prolonged. There will be changes in the treatments for prostate cancer. As the PARP inhibitors continue to be refined, they really will address advanced prostate cancer with more targeted therapies. Those are really interesting.
Then, in terms of immunotherapies for bladder cancers, some of those products like checkpoint inhibitors, which are drugs that allow T cells to stop tumors from growing in advanced bladder cancers, can hopefully prolong patients’ lives. So that too will be a good thing.
I really expect to see some big advancement in treatments for prostate cancer patients.”
Donald Sonn, MD